uploads/2018/06/Cardiovascular.png

The Performance of Johnson & Johnson’s Cardiovascular Segment

By

Updated

Cardiovascular segment revenue trends

Johnson & Johnson’s (JNJ) Cardiovascular segment generated revenues of $1.52 billion in the first quarter of 2018 compared to $1.48 billion in the first quarter of 2017, which reflected ~2.8% YoY growth.

In the US and international markets, Johnson & Johnson’s Cardiovascular segment generated first-quarter revenues of $1.1 billion and $414.0 million, respectively, which reflected ~1.0% and ~9.0% YoY growth.

Article continues below advertisement

Xarelto revenue trends

In the first quarter, Xarelto generated revenues of $587.0 million compared to $513.0 million in the first quarter of 2017, reflecting ~12.7% YoY growth.

Xarelto, a factor Xa blocker, is used in the treatment of pulmonary embolism and deep vein thrombosis. Xarelto is used in decreasing the risk of stroke and systemic embolism in individuals with nonvalvular atrial fibrillation. Clinical differentiation primarily pushed Xarelto’s growth and increase in market share, which was partially offset by higher discounts to managed care and government channels.

Xarelto’s peers include Boehringer Ingelheim’s Pradaxa and Bristol-Myers Squibb’s (BMY) Eliquis. In the first quarter, Eliquis reported revenues of $1.5 billion.

Invokana/Invokamet revenue trends

Johnson & Johnson’s Invokana reported revenues of $248.0 million in the first quarter compared to $284.0 million in the first quarter of 2017, reflecting an ~12.7% YoY decline.

Invokana generated revenues of $204.0 million and $44.0 million from the sales in the US and international markets, respectively, reflecting an ~17.4% decline and ~18.9% growth.

Contracting discounts, increasing utilization of Medicaid, and market share loss contributed to the decline of Invokana’s revenues in the first quarter. Invokana is used in the treatment of type 2 diabetes. Invokana’s primary peer in the marketplace, Eli Lilly’s (LLY) Jardiance, reported revenues of $151.0 million in the first quarter.

Procrit/Eprex: Revenue trends

Johnson & Johnson’s Procrit/Eprex generated revenues of $276.0 million in the first quarter compared to $247.0 million in the first quarter of 2017, reflecting ~11.7% YoY growth.

In the US and international markets, Procrit/Eprex generated first-quarter revenues of $189.0 million and $87.0 million, respectively. This compared to $169.0 million and $78.0 million in the first quarter of 2017, respectively, representing ~11.8% and ~11.5% YoY growth.

Procrit (epoetin alfa) is used for the management of anemia. Its peers in the marketplace include Amgen’s (AMGN) Aranesp and Epogen. Aranesp and Epogen reported first-quarter revenues of $225.0 million and $244.0 million, respectively,

Advertisement

More From Market Realist